Postoperative Imatinib in Patients with Intermediate Risk Gastrointestinal Stromal Tumor

References

• Joensuu H , FletcherC, DimitrijevicSet al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol.3, 655–664 (2002).
   PubMed Web of Science ®Google Scholar
• Maki RG . Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy. Curr. Treat. Options Gastroenterol.7, 13–17 (2004).
   PubMedGoogle Scholar
• Demetri GD , von MehrenM, BlankeCDet al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med.347, 472–480 (2002).
   PubMed Web of Science ®Google Scholar
• Zalcberg J , VerweijJ, CasaliPet al. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur. J. Cancer41, 1751–1757 (2005).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP , BallmanKV, AntonescuCRet al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet373, 1097–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Joensuu H , ErikssonM, HallKSet al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA307, 1265–1272 (2012).
   PubMed Web of Science ®Google Scholar
• Casali PG , Le CesneA, Poveda VelascoAet al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J. Clin. Oncol.36, 4276–4283 (2015).
   Google Scholar
• DeMatteo RP , BallmanKV, AntonescuCRet al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup Phase II trial. Ann. Surg.258, 422–429 (2013).
   PubMed Web of Science ®Google Scholar
• Li J , GongJ, WuAet al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur. J. Surg. Oncol.37, 319–324 (2011).
   PubMed Web of Science ®Google Scholar
• Joensuu H . Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol.39, 1411–1419 (2008).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP , LewisJJ, LeungDet al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg.231, 51–58 (2000).
   PubMed Web of Science ®Google Scholar
• Kang Y-K , KangBW, ImSAet al. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation. Cancer Chemother. Pharmacol.71, 43–51 (2013).
   PubMed Web of Science ®Google Scholar
• Gold JS , DeMatteoRP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann. Surgery244, 176–184 (2006).
   PubMed Web of Science ®Google Scholar
• Gold JS , van der ZwanSM, GönenMet al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann. Surg. Oncol.14, 134–142 (2007).
   PubMed Web of Science ®Google Scholar
• Gold JS , GönenM, GutiérrezAet al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol.10, 1045–1052 (2009).
   PubMed Web of Science ®Google Scholar
• Miettinen M , LasotaJ. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol.23, 70–83 (2006).
   PubMed Web of Science ®Google Scholar
• Corless CL , BallmanKV, AntonescuCRet al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J. Clin. Oncol.32, 1563–1570 (2014).
   PubMed Web of Science ®Google Scholar
• Agaimy A , VassosN, MärklBet al. Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach. Int. J. Colorectal Dis.28, 1057–1064 (2013).
   PubMed Web of Science ®Google Scholar
• Huynh T-K , MeeusP, CassierPet al. Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. BMC Cancer14, 156 (2014).
   PubMed Web of Science ®Google Scholar
• Heinrich MC , CorlessCL, DemetriGDet al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol.21, 4342–4349 (2003).
   PubMed Web of Science ®Google Scholar
• Andersson J , BümmingP, Meis-KindblomJMet al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology130, 1573–1581 (2006).
   PubMed Web of Science ®Google Scholar
• Weisberg E , WrightRD, JiangJet al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFR mutants with differential imatinib sensitivity. Gastroenterology131, 1734–1742 (2006).
   PubMed Web of Science ®Google Scholar
• Corless CL , SchroederA, GriffithDet al. PDGFR mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol.23, 5357–5364 (2005).
   PubMed Web of Science ®Google Scholar
• Fletcher CD , BermanJJ, CorlessCet al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int. J. Surg. Pathol.10, 81–89 (2002).
   PubMed Web of Science ®Google Scholar